NAMHAE-FOUNDATION
10.12.2021 09:02:11 CET | Business Wire | Press release
The beautiful islands of Namhae situated on the southern coast of Korea, over twelve hours away by flight from Europe, represent a small Europe with exotic sceneries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211210005088/en/
Celebrating the Visit Namhae County Year in 2022 , Namhae Foundation for Tourism and Culture introduces the best Namhae tourist attractions.
Namhae German Village: A Romantische Strasse, Rothenburg of Germany
Since its completion in 2003, the village’s white walls and orange-colored roofs became the symbol of Namhae, while beautifully tended gardens, German restaurants, beer pubs, and craft shops embody an exotic atmosphere. The German Village Beer Festival held in the village plaza in October is well-known in Korea.
Seomi Garden: Giverny of France, the Garden of Claude Monet
Beautiful scenery of four different seasonal flowers in bloom on stepped terrace fields overlooks the azure sea of Namhae. Built in the style of a European garden, Seomi Garden is reminiscent of Giverny, France, where the home with a garden of Impressionist painter Claude Monet is situated. Seomi Garden is an ideal location to take the most memorable photographs.
Gacheon Daraengi Village: Positano along the Amalfi Coast of Italy
The sight of the terraced paddy fields on the mountain slope facing the blue sea, alongside Amsubawi rocks, gives off an age-old sentiment unique to this village. Like Positano, there are steep steps to a village where visitors can walk along narrow winding roads in between low-rise buildings.
Namhae Yangtte Farm: The Alps of Switzerland
Namhae Yangtte Farm, located in a mountain, is comprised of a rolling plain dotted with white sheep under the blue sky and naturally echoes the vibes of the Alps. Visitors can pleasantly experience shepherding and feeding a herd of sheep or watch the famous shepherd dog Border Collies at work. The area comes with a trail lined with cypress trees.
Village House N Garden: Europe in One Place
House N Garden is a village built by 20 gardeners with 21 unique houses and gardens inspired by cultural themes of diverse countries. Visitors can enjoy a stroll and watch beautiful gardening works in homes along with sculptural and topiary gardens. Visitors can also find gardens inspired by Japanese and New Zealand cultures.
Balmy in winter and cool in summer, Namhae’s ideal climatic conditions make it an ideal travel destination: https://www.namhae.go.kr/tour/main.web .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211210005088/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
